Search Results - "Ways, D.Kirk"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    The role of protein kinase C in the development of the complications of diabetes by Ways, D.Kirk, Sheetz, Matthew J.

    Published in Vitamins and Hormones (2000)
    “…Diabetes mellitus produces a state of chronic hyperglycemia which in turn leads to the development of severe complications including retinopathy, nephropathy,…”
    Get full text
    Book Chapter Journal Article
  2. 2

    Phosphatidylinositol 3-kinase Contributes to Erk1/Erk2 MAP Kinase Activation Associated with Hepatocyte Growth Factor-induced Cell Scattering by Sipeki, Szabolcs, Bander, Erzsébet, Buday, László, Farkas, Gyöngyi, Bácsy, Ernõ, Ways, D.Kirk, Faragó, Anna

    Published in Cellular signalling (01-12-1999)
    “…MAP kinase cascade-dependent responses were investigated during scattering of HepG2 human hepatoma cells stimulated by HGF or phorbol ester. Inhibition of…”
    Get full text
    Journal Article
  3. 3

    Activation of Erk1/Erk2 and transiently increased p53 levels together may account for p21 expression associated with phorbol ester-induced transient growth inhibition in HepG2 cells by Sipeki, Szabolcs, Bander, Erzsébet, Ways, D.Kirk, Faragó, Anna

    Published in Cellular signalling (01-02-2002)
    “…In HepG2 cells grown in the presence of serum, enhanced Raf-activation correlated with transient growth inhibition. The activation of Raf was increased either…”
    Get full text
    Journal Article
  4. 4

    Protein kinase C decreases the hepatocyte growth factor-induced activation of Erk1/Erk2 MAP kinases by Sipeki, Szabolcs, Bander, Erzsébet, Farkas, Gyöngyi, Gujdár, Annamaria, Ways, D.Kirk, Faragó, Anna

    Published in Cellular signalling (01-08-2000)
    “…HGF and phorbol ester induce the scattering of HepG2 cells. Recently, we have reported that the motility and morphological responses that accompany this…”
    Get full text
    Journal Article
  5. 5

    Effects of protein kinase C inhibitors on thromboxane production by thrombin-stimulated platelets by Samokhin, Gennady P, Jirousek, Michael R, Ways, D.Kirk, Henriksen, Ruth Ann

    Published in European journal of pharmacology (15-12-1999)
    “…The purpose of these studies was to identify a possible role for protein kinase C in thromboxane production. The effects of four putative protein kinase C…”
    Get full text
    Journal Article
  6. 6

    Phorbol Ester-Stimulated Phosphorylation of PU.l: Association With Leukemic Cell Growth Inhibition by Carey, Julie O., Posekany, Karla J., deVente, James E., Pettit, George R., Ways, D.Kirk

    Published in Blood (15-05-1996)
    “…PU.1, a member of the ets transcription factor family, has been previously shown to be necessary for tetradecanoyl-phorbol-13 acetate (TPA)-induced U937…”
    Get full text
    Journal Article
  7. 7

    12-Deoxyphorbol-13-O-phenylacetate-20-acetate is not protein kinase C-beta isozyme-selective in vivo by Kiley, S C, Olivier, A R, Gordge, P C, Ryves, W J, Evans, F J, Ways, D K, Parker, P J

    Published in Carcinogenesis (New York) (01-02-1994)
    “…The phorbol ester, 12-deoxyphorbol-13-O-phenylacetate-20-acetate (DOPPA) has been shown to activate specifically the protein kinase C (PKC)-beta 1 isozyme in…”
    Get more information
    Journal Article
  8. 8

    Interleukin-3 induces translocation and down-regulation of protein kinase C in human platelets by Cook, P P, Chen, J, Ways, D K

    “…Protein kinase C (PKC) is a family of phospholipid-dependent kinases that is involved, along with calcium mobilization, in the activation of human platelets…”
    Get more information
    Journal Article
  9. 9

    Effects of Phorbol Esters on an Interleukin-3-Dependent Cell Line by McCubrey, James A., Steelman, Linda S., Sandlin, Gail, Riddle, Ruth S., Ways, D.Kirk

    Published in Blood (01-07-1990)
    “…FDC-P1 is an interleukin-3 (IL-3)-dependent cell line that ceases to proliferate in the absence of IL-3. We have isolated variant cell lines from FDC-P1 that…”
    Get full text
    Journal Article
  10. 10

    Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy by Teicher, B A, Alvarez, E, Mendelsohn, L G, Ara, G, Menon, K, Ways, D K

    Published in Advances in enzyme regulation (01-01-1999)
    “…The macrocyclic bisindolylmaleimide, LY333531, selectively inhibits protein kinase C beta 1 and beta 2 isoforms with an approximate IC50 of 5 nanomolar. The…”
    Get full text
    Journal Article